Melatonin treatment improves primary progressive multiple sclerosis: a case report

J Pineal Res. 2015 Mar;58(2):173-7. doi: 10.1111/jpi.12203. Epub 2015 Jan 13.

Abstract

We describe the case of a female patient who, at the age of 28, was diagnosed with symptoms of primary progressive multiple sclerosis (PPMS). Glucocorticoid treatment was immediately initiated. The disease and the demyelinating lesions progressed during the following 9 years reaching Expanded Disability Status Scale (EDSS) 8.0 (patient essentially restricted to bed, a chair or perambulated in a wheelchair). At this point, the patient began taking melatonin at doses ranging from 50 to 300 mg per day. Melatonin was her only treatment for the next 4 years; during this interval, her EDSS progressively recovered to 6.0 (the person needs intermittent or unilateral constant assistance such as cane, crutch, or brace to walk 100 meters with or without resting). This long-lasting improvement is likely due to melatonin usage since it is related in time and because of its exceptionally long duration.

Keywords: melatonin; multiple sclerosis; primary progressive multiple sclerosis.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Female
  • Humans
  • Melatonin / administration & dosage
  • Melatonin / therapeutic use*
  • Multiple Sclerosis / drug therapy
  • Multiple Sclerosis / pathology
  • Multiple Sclerosis, Chronic Progressive / drug therapy*
  • Multiple Sclerosis, Chronic Progressive / pathology

Substances

  • Melatonin